Press release from extraordinary shareholders meeting of Cereno Scientific AB
The extraordinary shareholders meeting of Cereno Scientific AB (publ) (Cereno or the Company) adopted the resolutions summarized below. The complete details regarding the resolutions are included in the information to the shareholders meeting, see the Company’s website, cerenoscientific.se.
Resolution regarding adoption of new articles of association
The Meeting resolved to adopt new articles of association whereby item 4 respectively 5 in the articles of association are amended according to that which is stated below.
Item 4 – Share capital
Previous wording (prior to the Meeting):
The share capital constitutes a minimum of SEK 500 000 and a maximum of SEK 2 000 000.
New wording:
The share capital constitutes a minimum of SEK 1 000 000 and a maximum of SEK 4 000 000.
Item 5 – Number of shares
Previous wording (prior to the Meeting):
The number of shares in the company shall be a minimum of 5 000 000 and a maximum of 20 000 000.
New wording:
The number of shares in the company shall be a minimum of 10 000 000 and a maximum of 40 000 000.
Resolution regarding the board’s decision to authorize new issue of shares and/or warrants and/or convertible notes
The Meeting resolved to authorize the board to, on one or more occasions during the period up to and including the next annual general meeting make decisions regarding new issue of shares and/or warrants and/or convertible notes against cash payment and/or with provisions on contribution in kind or set-off or otherwise with provisions and to therewith deviate from the shareholders’ right of first refusal.
Upon use of the authorization the subscription rate and other provisions shall be in accordance with the market, taking consideration marketable issue discounts in occurring cases.
The number of shares that can be issued respectively the number of shares that can be subscribed to with the support of option rights to subscribe for shares respectively the number of shares that convertible notes shall entitle to conversion shall in total amount to a maximum of such number that is possible within the limits of the articles of association upon full subscription, full conversion respectively fully exercising of option rights.
The purpose of the authorization and the reason for possible deviation from the shareholders’ right of first refusal is that it should be possible for issues to take place for financing of the company’s operations, commercialization and development of the company’s products and/or acquisition of operations, companies or portions of companies, and/or to enable an expansion of the ownership base in the company.
The board, chief executive office or the person the board provides are authorized to make such minor adjustments and clarification of the Meeting’s resolution, which can prove to be necessary in connection with the registration with the Swedish Companies Registration Office.
For further information, please contact:
Sten R. Sörensen – CEO
Tel: +46 73 374 03 74
Email: sten.sorensen@cerenoscientific.com
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. The benefit with Cereno Scientific’s drug candidate, CS1, is an improved balance between preventing thrombosis and treatment-related side effects – leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on AktieTorget since June 2016 with the ticker CRNO B, ISIN SE0008241558.
Tags: